|
Report Date : |
06.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
ALBRO PHARMACEUTICALS (PVT) LIMITED |
|
|
|
|
Registered Office : |
304-S,
Industrial Estate, Kot Lakhpat, Lahore-54000 |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
2003 |
|
|
|
|
Com. Reg. No.: |
0045264 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
|
|
|
|
No. of Employees : |
112 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
pakistan - ECONOMIC OVERVIEW
Decades of internal political disputes and low levels
of foreign investment have led to slow growth and underdevelopment in Pakistan.
Agriculture accounts for more than one-fifth of output and two-fifths of
employment. Textiles account for most of Pakistan's export earnings, and
Pakistan's failure to expand a viable export base for other manufactures has
left the country vulnerable to shifts in world demand. Official unemployment is
under 6%, but this fails to capture the true picture, because much of the
economy is informal and underemployment remains high. Over the past few years,
low growth and high inflation, led by a spurt in food prices, have increased
the amount of poverty - the UN Human Development Report estimated poverty in
2011 at almost 50% of the population. Inflation has worsened the situation,
climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in
2012. As a result of political and economic instability, the Pakistani rupee
has depreciated more than 40% since 2007. The government agreed to an
International Monetary Fund Standby Arrangement in November 2008 in response to
a balance of payments crisis. Although the economy has stabilized since the
crisis, it has failed to recover. Foreign investment has not returned, due to
investor concerns related to governance, energy, security, and a slow-down in
the global economy. Remittances from overseas workers, averaging about $1
billion a month since March 2011, remain a bright spot for Pakistan. However,
after a small current account surplus in fiscal year 2011 (July 2010/June 2011),
Pakistan's current account turned to deficit in fiscal year 2012, spurred by
higher prices for imported oil and lower prices for exported cotton. Pakistan
remains stuck in a low-income, low-growth trap, with growth averaging about 3%
per year from 2008 to 2012. Pakistan must address long standing issues related
to government revenues and energy production in order to spur the amount of
economic growth that will be necessary to employ its growing and rapidly
urbanizing population, more than half of which is under 22. Other long term
challenges include expanding investment in education and healthcare, adapting
to the effects of climate change and natural disasters, and reducing dependence
on foreign donors
|
Source : CIA |
ALBRO PHARMACEUTICALS
(PVT) LIMITED
|
Registered
Address |
|
304-S,
Industrial Estate, Kot Lakhpat, Lahore-54000, Pakistan |
|
Tel # |
92 (42) 35121121, 35117131 |
|
Fax # |
92 (42) 35120298 |
|
a. |
Nature of Business |
Manufacture & Marketing of
Pharmaceutical Products |
|
b. |
Year Established |
2003 |
|
c. |
Registration # |
0045264 |
|
In Karachi at present |
|
Ishtiaq Rana
& Co. (Chartered Accountants) 309, 3rd Floor, Eden Tower,
82-B-II, Main Boulevard, Gulberg II, Lahore, Pakistan |
|
Subject Company was incorporated as a Private Limited Company in 2003 |
|
Authorized Capital |
Rs. 5,000,000/-
divided into 50,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 1,000,000/-
divided into 10,000 shares of Rs. 100/- each |
|
Names |
Designation |
|
Mr. Abdul Aleem Eirabi Mr. Waseem Ahmed Eirabi Mr. Amir Aleem Mr. Nadeem Ahmed Mr. Naveed Ahmed |
Chief Executive Director Director Director Director |
|
Names |
No. of Shares |
|
Mr. Abdul Aleem Eirabi Mr. Waseem Ahmed Eirabi Mr. Amir Aleem Mr. Nadeem Ahmed Mr. Naveed Ahmed |
2,000 2,000 2,000 2,000 2,000 |
|
None |
Engaged in manufacture and marketing of Pharmaceutical Products by its
brand names of ACCRED, ALBACIT, ALBADROX, ALBAXIME, ALBAXONE, ALBOPLEX,
ALBROCEF, ALBROTRAN, ALFUR, BECOPAN, CEFBRO, DICBRO, FENRAM, FOLIC ACID,
GASTRIPAN, GIMED, KALCEE-D, MEGAFEN, MONODOX, ORTHOXEN, PARACETAMOL, PIMALBA,
QUIXET, RAYOVIT, REX, RIBAMAX, SAFE-T, SMYLE, SYDIP, SYLAC, SYREX, SYRO, SYZOL,
TEZDA, TORANT, VANAZOLE, VITAGRO
112
|
Year |
In Pak Rupees |
|
2011 |
120,000,000/- (Estimated) |
|
Mainly to Gulf & African Countries |
|
The capacity and production of the company’s
plant is indeterminable as it is multi-product and involves various processes
of manufacture. |
|
Mainly exist at major cities of Pakistan |
(1)
United Bank Limited, Pakistan.
(2)
The Bank of Punjab, Pakistan.
(3)
Habib Bank Limited, Pakistan.
(4)
MCB Bank Limited, Pakistan.
(5)
Standard Chartered Bank, Pakistan.
Pakistan Pharmaceutical Manufacturers Association.(PPMA)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 99.75 |
|
UK Pound |
1 |
Rs. 153.00 |
|
Euro |
1 |
Rs. 130.35 |
Subject Company
was established in 2003 and is engaged in manufacture & marketing of
Pharmaceutical Products. Trade relations are reported as fair. Subject can be
considered for normal business dealings at usual trade terms and
conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.95 |
|
|
1 |
Rs.83.80 |
|
Euro |
1 |
Rs.70.49 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.